Luke Nathaniel Walker - 17 Jun 2025 Form 4 Insider Report for Zentalis Pharmaceuticals, Inc. (ZNTL)

Reporting relationship: Director
Issuer ticker: ZNTL
Reported as of: 17 Jun 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 18 Jun 2025, 16:19:09 UTC
Prior SEC filing: 12 Jun 2025
Next SEC filing: 18 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Andrea Paul, attorney-in-fact for Luke Walker

Key filing fact

Luke Nathaniel Walker filed Form 4 for Zentalis Pharmaceuticals, Inc. (ZNTL) on 18 Jun 2025.

Key facts

This page summarizes Luke Nathaniel Walker's Form 4 filing for Zentalis Pharmaceuticals, Inc. (ZNTL).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 18 Jun 2025, 16:19.

Change

Previous filing in this sequence was filed on 12 Jun 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001701440 Primary reporting owner

Walker Luke Nathaniel

Relationship: Director
Address: C/O ZENTALIS PHARMACEUTICALS, INC., 10275 SCIENCE CENTER DRIVE, SUITE 200, SAN DIEGO
Signature: /s/ Andrea Paul, attorney-in-fact for Luke Walker
Signature date: 18 Jun 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ZNTL transaction

Common Stock

Award

Transaction value: $0
Shares: +57,603
Change %: +66%
Price: $0.000000
Shares after: 144,284
Date: 17 Jun 2025
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Represents restricted stock units granted pursuant to the Issuer's Non-Employee Director Compensation Program, each of which represents a contingent right to receive one share of common stock, and which will vest on the first to occur of (a) June 17, 2026 or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such vesting date.